Porownywarka

AOD-9604 vs Semaglutide side-by-side

Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.

Wybrane (2/4)

AOD-9604Semaglutide

Udostępnij porównanie peptydów

Wlasciwosc	AOD-9604	Semaglutide
Kategoria	Redukcja masy	Redukcja masy
Znany tez jako	Anti-Obesity Drug 9604, Tyr-hGH Fragment 177-191	Ozempic, Wegovy, Rybelsus
Zatwierdzony przez FDA	Nie	Tak
Status kliniczny	Clinical trials completed without FDA approval; source also reports Sept 2024 FDA Category 2 removal, expected Category 1 reclassification activity in 2026, and GRAS status. Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA	FDA-approved status recorded by the supplied source; it also reports several 2025-2026 indication and formulation updates. Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA
Czego oczekiwac	Fat loss, body composition, localized fat reduction	Weight loss, appetite control, blood sugar management
Jak dziala	AOD-9604 is described as a modified fragment of human growth hormone designed around the hormone's fat-metabolism region rather than the broader growth-hormone activity profile. The source reports lab and animal findings consistent with increased lipolysis and reduced lipogenesis. It also reports no meaningful IGF-1 increase, no glucose-metabolism harm in reviewed human safety evidence, and no settled receptor explanation, so the mechanism remains proposed rather than confirmed.	According to the supplied description, semaglutide stimulates the GLP-1 receptor. Reported downstream effects include increased insulin secretion when glucose is elevated, decreased glucagon, slower gastric emptying, and hypothalamic appetite signaling. A fatty-acid modification is described as promoting albumin binding and as associated with an approximately 160 hour (about 160 hours) half-life, supporting weekly administration.
Typowe dawkowanie	300 mcg daily · Once daily, usually morning fasted	1-2.4 mg weekly (after titration) · Once weekly
Dawkowanie z badań	250-500 mcg daily · 12-24 weeks in studies · Subcutaneous injection or oral	0.25mg weekly (starting) · Long-term / chronic use · Subcutaneous injection weekly, or oral (Rybelsus)
Typowy czas trwania	12-24 weeks in studies	Long-term / chronic use
Podanie	Subcutaneous injection or oral administration reported in studies	Subcutaneous injection weekly, or oral (Rybelsus)
Timing	Morning, fasted Empty-stomach use reported	Morning, same day each week With or without food
Poziom dowodów	Badania kliniczne	Zatwierdzone przez FDA
Mozliwe skutki uboczne	Generally very well-tolerated (Overall tolerability characterization reported by the source.) Injection-site reactions (Listed by the source as a reported side effect.) Mild headache (Reported as mild in the source.) +4 więcej Dizziness (Listed by the source as a reported side effect.) Does NOT produce typical HGH side effects (Source-reported absence of typical HGH-like effects; this does not establish individual safety.) No effect on IGF-1 levels (Source reports no IGF-1 increase in reviewed evidence.) GRAS status by expert panel (Reported safety-status item from the source rather than a symptom.)	Nausea (Common and usually transient; the source says reports vary with dose, duration, and individual health factors.) Vomiting Diarrhea +10 więcej Constipation Abdominal pain Headache Fatigue Injection site reactions Hypoglycemia (Source associates this report with insulin/sulfonylureas.) Gallbladder problems Pancreatitis Acute kidney injury Thyroid C-cell tumors (Boxed warning; the source lists a contraindication with MTC/MEN 2.)
Podsumowanie researchu	The supplied source presents a mixed evidence picture. It describes supportive cell and animal findings for fat-metabolism effects, then reports roughly six randomized, double-blind, placebo-controlled human trials involving about 900 participants. A cited safety review is summarized as finding good tolerability, no IGF-1 elevation, no glucose-metabolism harm, and no detectable antibodies. However, the source also states that the largest Phase IIb obesity trial did not beat placebo on its main weight-loss endpoint and that Metabolic Pharmaceuticals halted development around 2007.	The source characterizes the clinical literature as extensive. It reports that the SUSTAIN program established blood-sugar control in type 2 diabetes and that SUSTAIN 6 reduced cardiovascular events. For STEP 1, published in the New England Journal of Medicine in 2021, the source describes nearly 2,000 adults without diabetes in a randomized trial: at a 68 week endpoint, semaglutide 2.4 mg had 14.9 % mean weight loss versus 2.4 % with placebo, and most participants lost at least 5 %. It characterizes this as large randomized, placebo-controlled research rather than pilot data. Gastrointestinal effects, including nausea, vomiting, and constipation, were reported as most prominent during escalation; the source also reports an oral weight-management version as approved.
Referencje	Źródło Źródło +1 więcej Źródło	Źródło Źródło +2 więcej Źródło Źródło
Pełny profil	Zobacz szczegóły	Zobacz szczegóły

Zapisz to porównanie

Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.

Zapisz porównanie - darmowe konto

Trackuj swoja ścieżkę peptydówa

Zamien research w prywatny log protokołu, gdy będziesz gotowy.

Trackuj ścieżkę peptydówa

Wyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.

Wlasciwosc

AOD-9604

Semaglutide

Kategoria

Redukcja masy

Znany tez jako

Anti-Obesity Drug 9604, Tyr-hGH Fragment 177-191

Ozempic, Wegovy, Rybelsus

Zatwierdzony przez FDA

Nie

Tak

Status kliniczny

Clinical trials completed without FDA approval; source also reports Sept 2024 FDA Category 2 removal, expected Category 1 reclassification activity in 2026, and GRAS status.

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

FDA-approved status recorded by the supplied source; it also reports several 2025-2026 indication and formulation updates.

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Czego oczekiwac

Fat loss, body composition, localized fat reduction

Weight loss, appetite control, blood sugar management

Jak dziala

AOD-9604 is described as a modified fragment of human growth hormone designed around the hormone's fat-metabolism region rather than the broader growth-hormone activity profile. The source reports lab and animal findings consistent with increased lipolysis and reduced lipogenesis. It also reports no meaningful IGF-1 increase, no glucose-metabolism harm in reviewed human safety evidence, and no settled receptor explanation, so the mechanism remains proposed rather than confirmed.

According to the supplied description, semaglutide stimulates the GLP-1 receptor. Reported downstream effects include increased insulin secretion when glucose is elevated, decreased glucagon, slower gastric emptying, and hypothalamic appetite signaling. A fatty-acid modification is described as promoting albumin binding and as associated with an approximately 160 hour (about 160 hours) half-life, supporting weekly administration.

Typowe dawkowanie

300 mcg daily · Once daily, usually morning fasted

1-2.4 mg weekly (after titration) · Once weekly

Dawkowanie z badań

250-500 mcg daily · 12-24 weeks in studies · Subcutaneous injection or oral

0.25mg weekly (starting) · Long-term / chronic use · Subcutaneous injection weekly, or oral (Rybelsus)

Typowy czas trwania

12-24 weeks in studies

Long-term / chronic use

Podanie

Subcutaneous injection or oral administration reported in studies

Subcutaneous injection weekly, or oral (Rybelsus)

Timing

Morning, fasted

Empty-stomach use reported

Morning, same day each week

With or without food

Poziom dowodów

Badania kliniczne

Zatwierdzone przez FDA

Mozliwe skutki uboczne

Generally very well-tolerated (Overall tolerability characterization reported by the source.)
Injection-site reactions (Listed by the source as a reported side effect.)
Mild headache (Reported as mild in the source.)

+4 więcej

Dizziness (Listed by the source as a reported side effect.)
Does NOT produce typical HGH side effects (Source-reported absence of typical HGH-like effects; this does not establish individual safety.)
No effect on IGF-1 levels (Source reports no IGF-1 increase in reviewed evidence.)
GRAS status by expert panel (Reported safety-status item from the source rather than a symptom.)

Nausea (Common and usually transient; the source says reports vary with dose, duration, and individual health factors.)
Vomiting
Diarrhea

+10 więcej

Constipation
Abdominal pain
Headache
Fatigue
Injection site reactions
Hypoglycemia (Source associates this report with insulin/sulfonylureas.)
Gallbladder problems
Pancreatitis
Acute kidney injury
Thyroid C-cell tumors (Boxed warning; the source lists a contraindication with MTC/MEN 2.)

Podsumowanie researchu

The supplied source presents a mixed evidence picture. It describes supportive cell and animal findings for fat-metabolism effects, then reports roughly six randomized, double-blind, placebo-controlled human trials involving about 900 participants. A cited safety review is summarized as finding good tolerability, no IGF-1 elevation, no glucose-metabolism harm, and no detectable antibodies. However, the source also states that the largest Phase IIb obesity trial did not beat placebo on its main weight-loss endpoint and that Metabolic Pharmaceuticals halted development around 2007.

The source characterizes the clinical literature as extensive. It reports that the SUSTAIN program established blood-sugar control in type 2 diabetes and that SUSTAIN 6 reduced cardiovascular events. For STEP 1, published in the New England Journal of Medicine in 2021, the source describes nearly 2,000 adults without diabetes in a randomized trial: at a 68 week endpoint, semaglutide 2.4 mg had 14.9 % mean weight loss versus 2.4 % with placebo, and most participants lost at least 5 %. It characterizes this as large randomized, placebo-controlled research rather than pilot data. Gastrointestinal effects, including nausea, vomiting, and constipation, were reported as most prominent during escalation; the source also reports an oral weight-management version as approved.

Referencje

+1 więcej

+2 więcej

Pełny profil